Close Menu

genetic testing

The authors of the study noted that these genetic findings could guide better clinical decisions for patients and improve outcomes.

Researchers found that more than 3 percent of postmenopausal women with breast cancer but no other disease risk factors carried pathogenic variants. 

The CVS-Tempus partnership aims to streamline the cancer care process for patients from the point of prescribing onwards and connect patients with local trials.

Currently available under a soft launch, the tool can provide information about the prevalence of cancer risk mutations based on patients' demographics.

Color researchers reported that 21.7 percent of individuals with pathogenic variants in well-established genes did not meet guidelines for testing.

Stanford University's Allison Kurian and her colleagues found that women with pathogenic variants were more likely to undergo a bilateral mastectomy.

The assay can identify KRAS, NRAS, PIK3CA, BRAF, and EGFR gene mutations, as well as 19 gene rearrangements of the ALK, ROS1, RET, NTRK1, and MET genes from FFPE.

The analysis from Quest Diagnostic researchers compared the cost-effectiveness of a seven-gene panel test to BRCA1 and BRCA2 testing alone in improving life expectancy.